Healthcare Royalty Partners

Healthcare Royalty Partners

Healthcare Royalty Partners (HCRx) was formed in 2006 by Todd Davis and Clarke Futch, previously the senior team behind Paul Capital Partners' healthcare royalty business. The firm operates from Stamford, Connecticut, and focuses exclusively on acquiring royalty interests in FDA-approved or late-stage biopharmaceutical products, a niche that isolates clinical risk from the revenue stream. This model buys future royalty cash flows from universities, inventors, and smaller biotechs that need upfront capital rather than equity dilution. HCRx targets royalty streams on therapeutics and diagnostics that have already cleared key regulatory hurdles, spanning oncology, rare disease, and specialty pharmaceuticals. The firm acquires both direct royalty interests and synthetic royalty structures, often writing checks between $25 million and $200 million per transaction. Its current vehicle, HCR Royalty Fund III, closed in 2021 and continues its predecessor funds' strategy of building diversified pools of royalty-linked cash flows. Known royalties in its portfolio have included agreements tied to Vertex's cystic fibrosis franchise and BioMarin's enzyme-replacement therapies, though the firm does not publicly disclose full holdings. The firm's team blends structured-finance expertise with deep biopharma domain knowledge, and though exact headcount is not publicly disclosed, its investment committee is led by Davis and Futch alongside a senior group of investment professionals. In addition to its flagship royalty funds, HCRx has occasionally co-invested alongside other healthcare-focused credit funds. HCR Royalty Partners III was reported to be targeting $1.7 billion in commitments, per media reports at the time of its launch, and continues to actively acquire new royalty positions. HCRx occupies a unique structural position within healthcare investing: while most healthcare PE and venture funds take equity risk, HCRx deals in contractually-defined revenue shares on already-commercialized products. This means its returns are less correlated with binary drug-trial outcomes and more tied to prescription volume and pricing dynamics. The firm runs no clinical trials, employs no bench scientists, and operates as a specialized healthcare credit and royalty platform rather than a traditional equity investor.